Investment Rating - The report maintains an investment rating of "Outperform" [6] Core Insights - The report highlights the potential of small nucleic acid drugs in weight loss applications, validated by Arrowhead Pharmaceuticals' recent data on INHBE and ALK7 targeted siRNA drugs [3][28] - The new drug sector has shown significant price movements, with notable gains from companies like Frontline Bio (+55.96%) and Shengnuo Pharma (+27.25%) during the week of January 5 to January 11, 2026 [1][16] - There are multiple catalysts expected in the sector, including academic conferences and data releases, which could drive further interest in specific companies [2] Weekly New Drug Market Review - From January 5 to January 11, 2026, the top five gainers in the new drug sector were Frontline Bio (+55.96%), Shengnuo Pharma (+27.25%), Rongchang Bio (+24.64%), Yifang Bio (+22.61%), and Zhixiang Jintai (+19.09%) [1][16] - The top five decliners included Jiahe Bio (-10.69%), Junsheng Tai (-10.56%), Beihai Kangcheng (-5.51%), Yongtai Bio (-3.15%), and Laikai Pharma (-1.84%) [1][16] Weekly Focus on Recommended Stocks - Companies with high overseas growth potential certified by MNCs include Sanofi Pharma, Lianbang Pharma, and Kelun Biotech [2] - Companies with overseas data catalysts include Betta Pharma, Hutchison China MediTech, and Yingen Bio [2] - Potential heavyweights for overseas licensing include Fuhong Hanlin, CSPC Pharmaceutical Group, and Yifang Bio [2] - New innovative drug technology breakthroughs are expected in areas such as small nucleic acids, in vivo CAR-T, fat loss and muscle gain, autoimmune CAR-T/bispecific antibodies, and gene therapy [2] New Drug Industry Key Analysis - Arrowhead Pharmaceuticals has disclosed early weight loss data for its INHBE-targeted siRNA drug, further validating the application potential of small nucleic acid drugs in weight loss [3][28] - Domestic companies are actively developing INHBE-targeted siRNA drugs, including major players like Dairui Bio, Shengyin Bio, and Bowe Pharmaceutical [3][34] - The ALK7-targeted siRNA drug ARO-ALK7 has shown promising results, with a significant reduction in visceral fat observed in clinical trials [40][41] New Drug Approval and Acceptance Status - This week, 8 new drug or new indication applications were approved in China, while 20 applications were accepted [4][43] - The approved drugs include various formulations and indications, such as the injection of human thyroid-stimulating hormone beta and the injection of relaflufin alpha [44] New Drug Clinical Application Approval and Acceptance Status - A total of 47 new drug clinical applications were approved this week, with 46 applications accepted [10][48]

Investment Rating - The industry is rated as "Outperforming the Market - A" with a maintained rating [4] Core Insights - Nvidia has launched the next-generation Rubin AI platform, which is set to significantly enhance training performance by 3.5 times and improve AI software performance by 5 times compared to the previous Blackwell platform. The platform will reduce inference token generation costs by up to 10 times and decrease the number of GPUs required for training mixture of experts models by 4 times [1] - Nvidia's new AI-native storage infrastructure, driven by BlueField-4, aims to address the growing AI storage demand, which has surpassed existing infrastructure capacity. This new architecture is designed specifically for AI inference, enhancing efficiency and energy optimization [2] - TSMC has begun mass production of its 2nm process technology, with initial monthly capacity of 35,000 wafers, expected to increase to 140,000 wafers by the end of 2026, surpassing previous market estimates [3] Industry Performance - The electronic sector has shown a relative return increase of 4.8% over the past month and an absolute return of 8.3% [6] - The electronic index has risen by 7.74% in the past week, ranking 7th out of 31 industries [30] - The semiconductor sub-sector has seen a significant increase of 10.61% in the same period, indicating strong performance within the industry [35] Investment Recommendations - For the semiconductor sector, companies such as SMIC, Hua Hong Semiconductor, and Northern Huachuang are recommended for investment. In the consumer electronics sector, companies like Luxshare Precision, Lens Technology, and Goertek are highlighted as potential investment opportunities [10]

Investment Rating - The report maintains an investment rating of "Outperform" with a rating of A [7] Core Insights - The gas turbine industry is experiencing a tightening global capacity, with domestic supply chains poised to capture the benefits of the AIDC boom [1] - Gas turbines are recognized for their high efficiency and flexibility, making them a preferred choice for power generation [1][34] - The demand for gas turbines is expected to grow significantly due to the rapid expansion of AIDC and the need for equipment replacement [2] - The supply side is characterized by high market concentration, with major players like GEV, Siemens Energy, and Mitsubishi Heavy Industries holding approximately 85% market share [3] - Investment opportunities are highlighted in companies with customer positioning advantages and rigid supply chains [4] Summary by Sections 1. Gas Turbines: Efficient and Flexible Power Generation Equipment - Gas turbines convert fuel energy into mechanical power through a continuous flow of gas, widely used in power generation, transportation, and industrial applications [1] - They are categorized into heavy, medium, small, and aeroderivative types, with heavy-duty turbines being the preferred model for utility power due to their high efficiency and rapid load response [1][24] 2. Demand: Rapid Expansion of AIDC and Replacement Cycle - The AIDC construction scale is rapidly expanding, with gas turbines expected to increase their share in the U.S. data center power supply from 40% in 2024 to over 50% by 2035 [2] - Global annual new installation demand for gas turbines in data centers is projected to exceed 30GW from 2026 to 2030, representing a growth of over 50% compared to the 2016-2023 average [2][4] 3. Supply: Highly Concentrated Market with Tight Overseas Capacity - The market is highly concentrated, with GEV, Siemens Energy, and Mitsubishi Heavy Industries maintaining high order intake and revenue levels [3] - The supply of core components like turbine blades is constrained due to high technical barriers, creating opportunities for domestic supply chain companies to capture market share [3] 4. Investment Recommendations: Focus on Quality Companies with Customer Positioning Advantages - The report recommends focusing on companies with strong customer positioning, supply rigidity, and high certainty of volume growth, including companies like Yingliu Technology, Eagle Precision, and others [4]

Investment Rating - The industry investment rating is maintained at "Outperform the Market - A" [4] Core Views - The sulfur price is experiencing fluctuations due to supply-demand dynamics, with a short-term supply guarantee not fundamentally altering the long-term tight resource situation. The expected global sulfur supply-demand gap for 2026 is projected to be -5.13 million tons, indicating a strategic revaluation of sulfur resources in the long term [2][16] - The recent restructuring between Sinopec and China Aviation Oil is expected to enhance the integration of oil refining and distribution, potentially accelerating the commercial use of Sustainable Aviation Fuel (SAF) in China [3][7] Summary by Sections 1. Core Insights of the Week - The market is witnessing a rebound in oil prices, with Brent crude reaching $63.05 per barrel, reflecting a 3.7% increase. This is driven by geopolitical tensions affecting supply expectations [14] - The chemical sector is gaining attention due to a better-than-expected Producer Price Index (PPI) recovery, indicating potential for upward valuation in the sector [15] 2. Chemical Sector Performance - The basic chemical industry index increased by 3.7% in the week, outperforming major indices like the Shanghai Composite and ChiNext [21] - Among 26 sub-sectors, 25 experienced gains, with the top performers being modified plastics (+9.5%) and inorganic salts (+7.2%) [26] 3. Stock Performance in the Chemical Sector - In the basic chemical sector, 373 out of 424 stocks rose, with notable gainers including Prit (42.6%) and Sanfu (32.3%). Conversely, stocks like Evergrande High-Tech saw declines of 13.1% [28][29] 4. Investment Focus Areas - The report suggests focusing on four main investment lines: 1. Upstream resource assets with strong profit certainty, particularly in phosphorus and sulfur [16] 2. Supply-side optimization under "anti-involution" policies, targeting sectors with high concentration and price elasticity [17] 3. Low-valued leading stocks in the sector, as capital expenditure cycles slow down [18] 4. New productivity investments aligned with green energy and advanced materials [20]

Investment Rating - The investment rating for the company is "Buy-A" with a 12-month target price of 7.35 yuan, while the current stock price is 6.18 yuan [5]. Core Insights - The company has signed a strategic cooperation agreement with Jingtai Technology to develop AI+robotics high-throughput perovskite solar cell technology, aiming to enhance competitive advantages in photovoltaic products [1][2]. - The perovskite tandem technology is seen as a key direction for the future of the photovoltaic industry, with the company achieving a new breakthrough in conversion efficiency of 34.76% for its TOPCon-based perovskite tandem cells [3]. - The energy storage business is expected to turn profitable soon, with a projected shipment volume of 3.3 GWh in the first three quarters of 2025 and plans for significant growth in 2026 [4]. Summary by Sections Strategic Cooperation - The collaboration aims to create the world's first AI-driven, robot-executed, and data-feedback closed-loop manufacturing line for tandem solar cells, significantly improving research and development efficiency [2]. - The new experimental line is expected to achieve a throughput of 1000 cells per day, enhancing R&D efficiency by a factor of 100 [2]. Technological Advancements - The company has improved its TOPCon cell efficiency to 27.79% and plans to upgrade 40%-50% of its existing capacity by the end of 2025, with mainstream models exceeding 640W [3]. - The strategic partnership is crucial for consolidating the company's long-term technological advantages and capturing the next generation of technology leadership [3]. Energy Storage Business - The company is deepening its strategic layout in the new energy storage sector, with a focus on large-scale and commercial energy storage projects, achieving an international order ratio of approximately 80% [4]. - The energy storage business is anticipated to contribute stable profits starting in 2026, supported by a production capacity of 17 GWh for system integration and 5 GWh for cell self-supply [4]. Financial Projections - The company is projected to have net profits of -4.5 billion yuan in 2025, followed by 2.13 billion yuan in 2026 and 3.57 billion yuan in 2027, indicating a significant turnaround [9]. - The company is compared with peers like Longi Green Energy, JA Solar, and Trina Solar, highlighting its leading position in TOPCon technology and rapid growth in the energy storage sector [9].

Investment Rating - The investment rating for the company is "Buy-A" with a 12-month target price of 71.95 CNY per share [4]. Core Insights - The report highlights that the company is entering a significant growth phase with multiple new products in the domestic market and the overseas market poised for key data readouts, particularly for the long-acting eye drug EYP-1901 [1][2][3]. Summary by Sections Overseas Market - EYP-1901, a long-acting eye drug, is expected to read out phase 3 clinical data for wet age-related macular degeneration (wAMD) by mid-2026, which could catalyze significant market potential [2][24]. - The competitive landscape for VEGF small molecule eye drugs is favorable, with EYP-1901 leading in development progress [2][30]. - EYP-1901 offers a differentiated advantage with a dosing frequency of once every six months, which is expected to significantly improve patient adherence compared to current treatments like Aflibercept, which requires dosing every two months [2][34]. Domestic Market - The company has several new products entering a rapid growth phase, including plant-derived recombinant albumin and long-acting factor VIII, which are expected to capture significant market share [3][21]. - The sales of Enasidenib and Bevacizumab are accelerating, indicating strong growth potential in the lung cancer and other oncology markets [3][21]. - Revenue projections for the company are optimistic, with expected revenues of 3.55 billion CNY, 4.46 billion CNY, and 5.48 billion CNY for 2025, 2026, and 2027 respectively, alongside net profits of 409 million CNY, 704 million CNY, and 896 million CNY for the same years [3][8]. Financial Forecast - The company is projected to achieve a revenue growth rate of approximately 15.9% year-on-year for the first three quarters of 2025, driven by the launch of multiple new drugs [17][21]. - The earnings per share (EPS) are expected to increase from 0.97 CNY in 2025 to 2.13 CNY in 2027, reflecting a strong growth trajectory [8][21].

Investment Rating - The industry investment rating is "Leading the Market - A" [6] Core Insights - The restructuring of Sinopec and China Aviation Oil aims to enhance core competitiveness and optimize state-owned capital layout, addressing the issue of homogeneous competition in the aviation fuel sector [2][3] - The global aviation fuel demand is projected to grow to 389 million tons by 2025, with a year-on-year increase of 3.9%, indicating significant growth potential in this sector [3] - The merger will allow Sinopec to integrate its refining and distribution capabilities, while China Aviation Oil will benefit from a more stable upstream supply, enhancing the overall efficiency and cost-effectiveness of aviation fuel supply [3][4] Summary by Sections Restructuring Purpose - The restructuring aligns with recent state-owned enterprise reforms focused on core business enhancement and competitive advantage [2] - China Aviation Oil's current business model is primarily trade-oriented, necessitating a shift towards integration with larger state-owned enterprises [2] Strategic Significance - The merger is expected to create a comprehensive supply chain from refining to aircraft refueling, reducing intermediary costs and improving energy security for China's aviation industry [3] - The combined strengths of both companies will facilitate advancements in Sustainable Aviation Fuel (SAF) technology and its commercial application [4][6] Impact on SAF Industry - Sinopec is a pioneer in SAF production in China, having successfully tested its products on domestic aircraft models [4] - The merger will enhance the technological and operational capabilities in SAF development, promoting its large-scale commercialization and contributing to carbon reduction in the aviation sector [6]

Investment Rating - The investment rating for the pharmaceutical industry is "Outperform the Market - A" [6] Core Insights - The report indicates that the global market for innovative drug VC&PE financing is experiencing a sustained recovery in 2025, serving as a leading indicator for the CXO industry's economic conditions [1][9] - In 2025, the global innovative drug VC&PE financing amount is projected to grow by 3.39% year-on-year, improving by 1.46 percentage points compared to 2024 [2][10] - The report highlights significant improvements in the growth rates of VC&PE financing for innovative drugs in Q4 2025, with global, U.S., and domestic financing amounts increasing by 22.05%, 29.86%, and 46.34% year-on-year, respectively [3][11] - In December 2025, the financing amounts for innovative drugs in the global, U.S., and domestic markets saw year-on-year growth rates of 21.31%, 57.02%, and 50.42%, respectively, with particularly strong growth in the U.S. and domestic markets [4][20] Summary by Sections 1. Annual Observation - The report notes that the low point for global innovative drug VC&PE financing occurred in 2022, with a narrowing decline in 2023 and a return to positive growth in 2024-2025 [2][10] 1.2 Quarterly Observation - In Q4 2025, the growth rates for global, U.S., and domestic innovative drug VC&PE financing improved significantly compared to Q3 2025, with increases of 23.59, 27.94, and 13.97 percentage points, respectively [3][11] 1.3 Monthly Observation - December 2025 saw high year-on-year growth in global, U.S., and domestic innovative drug VC&PE financing, with the U.S. and domestic markets showing particularly notable increases [4][20]

Investment Rating - The investment rating for the company is "Accumulate-A" with a target price of 7.35 yuan [6]. Core Insights - The company has a stable heating business and is actively transforming into a new type of comprehensive energy service provider, leveraging its advantages in location and cost [2]. - The clean heating business includes various technologies such as cogeneration, water source heat pumps, and biomass cogeneration, with a focus on expanding its service area in Shenyang [2]. - The high-speed rail media segment has faced short-term profit pressure but is expected to recover as new business developments are completed [3]. - Hydrogen energy is included in the "14th Five-Year Plan," which is anticipated to contribute to new growth opportunities for the company [4]. Financial Performance Summary - From 2018 to 2020, the company's revenue grew from 3.037 billion yuan to 3.598 billion yuan, with a compound annual growth rate (CAGR) of 8.8%, and net profit increased from 1.317 billion yuan to 1.685 billion yuan, with a CAGR of 13.14% [1]. - Revenue is expected to stabilize around 3.5 billion yuan from 2020 to 2024, with a projected net profit of 659 million yuan in 2024, a year-on-year decline of 23.29% due to impairment losses [1]. - The company has maintained a high dividend payout ratio, with dividends of 475 million yuan, 447 million yuan, and 711 million yuan from 2022 to 2024, representing payout ratios of 50.26%, 52.02%, and 108.02% respectively [1]. Business Segment Analysis - The heating and steam segment is expected to generate revenues of 2.359 billion yuan, 2.413 billion yuan, and 2.473 billion yuan from 2025 to 2027, with improving gross margins due to declining coal prices [18]. - The power generation business is projected to maintain stable revenues of 134 million yuan, 136 million yuan, and 139 million yuan over the same period, with gross margins of 3% [18]. - The engineering segment is expected to decline due to the overall slowdown in the real estate sector, with revenues forecasted at 168 million yuan, 151 million yuan, and 136 million yuan [18]. - The advertising business, driven by the high-speed rail media segment, is expected to recover, with revenues projected at 685 million yuan, 719 million yuan, and 791 million yuan from 2025 to 2027 [18].

Investment Rating - The report assigns a "Buy-A" investment rating to the company for the first time, with a target price of 6.69 HKD over the next six months [4][3]. Core Insights - The company is positioned as a leading dairy farm in China, benefiting from the anticipated rebound in raw milk prices and beef prices, which is expected to enhance profit elasticity [3][9]. - The report forecasts revenue growth rates of 1.2%, 9.6%, and 12.7% for the years 2025 to 2027, with net profits projected at 0.1 billion, 15.7 billion, and 27.1 billion CNY respectively [3][9]. Summary by Relevant Sections Raw Milk Cycle - By December 2025, raw milk prices have decreased by 31% from their peak in August 2021, marking nearly four and a half years of decline. A rebound is expected in 2026 due to factors such as the aging of the cow herd and the expiration of large powder stocks, which will drive demand for fresh raw milk [1][2]. - The company is expected to benefit significantly from the recovery in raw milk prices, which will enhance its gross profit margins from raw milk sales [1][3]. Beef Cycle - The price of live cattle has also entered a new upward cycle after a decline of 31% from its peak in January 2023 to a low in February 2025. The report anticipates that live cattle prices will continue to rise in 2026, benefiting the company's income from the sale of culled cattle [2][3]. - The company is projected to earn approximately 700 million CNY from the sale of culled cattle in 2024, which will be positively impacted by the rising prices of live cattle [2][3]. Financial Projections - The company is expected to generate revenues of 20.33 billion CNY in 2025, 22.28 billion CNY in 2026, and 25.11 billion CNY in 2027, with corresponding net profits of 0.1 billion, 1.57 billion, and 2.71 billion CNY [8][9]. - The gross margin for raw milk sales is projected to improve from 33.7% in 2025 to 38.1% in 2027, reflecting the company's operational efficiency and favorable market conditions [10][9].